Journal of Urologic Oncology

Kidney Cancer

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study: Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park; Journal of Urologic Oncology. 2024;22(1):59-67. Published online March 31, 2024; DOI: https://doi.org/10.22465/juo.234600660033
Cited By 1; Full text PubReader ePub PDF

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer

Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023: Jiwoong Yu, Hyun Hwan Sung; Journal of Urologic Oncology. 2023;21(3):228-240. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600420021
Cited By 2; Full text PubReader ePub PDF

Trimodality Therapy and Immuno-Oncology for Bladder Cancer

The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials: Sang Hun Song, Jong Jin Oh; Journal of Urologic Oncology. 2023;21(2):154-164. Published online July 31, 2023; DOI: https://doi.org/10.22465/juo.234600300015
Cited By 3; Full text PubReader ePub PDF

De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors: Sung Han Kim, Eun Young Park, Hyung-Ho Lee, Jinsoo Chung, Ho Kyung Seo; Korean J Urol Oncol. 2022;20(1):25-33. Published online February 24, 2022; DOI: https://doi.org/10.22465/kjuo.2022.20.1.25; Full text PubReader ePub PDF

New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Jaewoon Jeong, Jae Baek Ha, In Ho Chang; Korean J Urol Oncol. 2022;20(1):12-24. Published online February 24, 2022; DOI: https://doi.org/10.22465/kjuo.2022.20.1.12; Full text PubReader ePub PDF

The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers: Gwang Yong Hwang, Se Young Choi, In Ho Chang; Korean J Urol Oncol. 2019;17(2):75-80. Published online August 30, 2019; DOI: https://doi.org/10.22465/kjuo.2019.17.2.75; Full text PubReader ePub PDF

6,001	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
5,464	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
4,974	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
4,815	Complex Epidemiology of Prostate Cancer in Asian Countries
4,680	The Present and Future of Intravesical Therapy in Bladder Cancer

Cited By 9	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 4	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By 4	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 3	The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use

Search